Agalimmune is exploring strategic partnerships to enhance the development and commercialisation of immunotherapies. We want to hear from companies and institutions that share our ethos and dedication for advancing the science of cancer treatments to improve patient health and wellbeing.
In particular we see synergies with those interested in working on:
- The development of potentially symbiotic compounds, such as immune checkpoint blockade agents looking to increase targeting, efficacy, potentially reduce dose & ameliorate side effect profile.
- R&D projects to study Agalimmune’s compounds against solid tumors in both clinical and preclinical settings with a view to publishing data.